CAS: 916918-84-8; 4-[2-Dimethylamino-1-(1-Hydroxycyclohexyl)Ethyl]Phenyl 4-Methylbenzoate Hydrochloride

主要参考文献

1: Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H. Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry. Pharmacopsychiatry. 2022 Jul;55(4):193-202. doi: 10.1055/a-1714-9097. Epub 2022 Jan 19.
2: Mi W, Yang F, Li H, Xu X, Li L, Tan Q, Wang G, Zhang K, Tian F, Luo J, Xia J, Yuan K, Lu L, Deng J, Tian J, Zhang H. Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):252-260. doi: 10.1093/ijnp/pyab074.
3: Mi W, Di X, Wang Y, Li H, Xu X, Li L, Wang H, Wang G, Zhang K, Tian F, Luo J, Yang C, Zhou Y, Xie S, Zhong H, Wu B, Yang D, Chen Z, Li Y, Chen J, Lv S, Yi Q, Jiang Z, Tian J, Zhang H. A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Transl Psychiatry. 2023 May 10;13(1):163. doi: 10.1038/s41398-023-02435-0.

合成参考文献

摘要:Wolff A. [Problem of occupational disability hazards]. Lebensversicher Med. 1976 May;28(3):76–7.